What is Kalaris Therapeutics Inc's earnings per share (EPS)?

Kalaris Therapeutics Inc (KLRS) reported diluted earnings per share of $-2.85 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kalaris Therapeutics Inc Financials

KLRS

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Kalaris Therapeutics Inc (KLRS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KLRS FY2025 2026-04-22

A 2025 financing reset rebuilt liquidity, but Kalaris still functions as a cash-burning development company without an internal funding engine.

In one year, cash reserves jumped from $1.6M to $98.1M, moving the company from a near-term liquidity squeeze to a far more workable operating position. But that balance-sheet repair came from $155.0M of financing cash flow while operations still used -$38.4M, so the stronger footing was supplied by investors rather than by the business funding itself.

Earnings quality is relatively straightforward for this stage: net loss was -$43.4M and free cash flow was -$38.6M, which are close enough to show that accounting losses are mostly real cash spending. That matters because capex is minimal, so the burn is tied mainly to running the development effort year to year, not to building a capital-heavy operating base.

Cost structure remains centered on development work, with R&D at $30.8M versus SG&A of $15.4M, so the company is still organized around research activity rather than supporting commercial activity. Compared with FY2023, the much smaller expense base points to a reset in operating scale rather than a business reaching self-sustaining economics, especially with no reported revenue base to absorb research spending or replenish cash internally.

Financial Health Signals

Financial Profile 32/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Kalaris Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Kalaris Therapeutics Inc carries a low D/E ratio of 0.54, meaning only $0.54 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 91/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 12.23, Kalaris Therapeutics Inc holds $12.23 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Kalaris Therapeutics Inc generates a -55.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.

Piotroski F-Score Weak

2/9

Kalaris Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.88x

For every $1 of reported earnings, Kalaris Therapeutics Inc generates $0.88 in operating cash flow (-$38.4M OCF vs -$43.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-32.0x

Kalaris Therapeutics Inc earns $-32.0 in operating income for every $1 of interest expense (-$46.2M vs $1.4M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$46.1M

Kalaris Therapeutics Inc's EBITDA was -$46.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$43.4M

Kalaris Therapeutics Inc reported -$43.4M in net income in fiscal year 2025.

EPS (Diluted)

$-2.85

Kalaris Therapeutics Inc earned $-2.85 per diluted share (EPS) in fiscal year 2025. This represents an increase of 94.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$38.6M

Kalaris Therapeutics Inc generated -$38.6M in free cash flow in fiscal year 2025, representing cash available after capex.

Cash & Debt

$98.1M

YoY+5882.6%

5Y CAGR-4.4%

Kalaris Therapeutics Inc held $98.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

23M

Kalaris Therapeutics Inc had 23M shares outstanding in fiscal year 2025. This represents an increase of 1588.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-55.1%

5Y CAGR-35.3pp

Kalaris Therapeutics Inc's ROE was -55.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

$30.8M

5Y CAGR-9.1%

Kalaris Therapeutics Inc invested $30.8M in research and development in fiscal year 2025.

Share Buybacks

N/A

Capital Expenditures

$200K

5Y CAGR-3.2%

Kalaris Therapeutics Inc invested $200K in capex in fiscal year 2025, funding long-term assets and infrastructure.

KLRS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$30.8M	N/A	$133.1M+11.9%	$118.9M-1.5%	$120.7M+143.1%	$49.7M
SG&A Expenses	$15.4M+130.2%	$6.7M-86.1%	$48.3M-7.8%	$52.3M+6.6%	$49.1M+126.8%	$21.6M
Operating Income	-$46.2M	N/A	-$199.9M-16.8%	-$171.2M-0.8%	-$169.8M-138.1%	-$71.3M
Interest Expense	$1.4M-46.6%	$2.7M	N/A	N/A	N/A	N/A
Income Tax	$0	$0+100.0%	-$126K+52.5%	-$265K-126.3%	$1.0M	N/A
Net Income	-$43.4M	N/A	-$190.4M-12.9%	-$168.7M+1.9%	-$172.0M-146.4%	-$69.8M
EPS (Diluted)	$-2.85	$-51.77	$-42.09	$-2.20+19.7%	$-2.74	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$9.1M+8.1%	$8.4M+40.0%	$6.0M	N/A	$36.0M+1021.8%	$3.2M+63.7%	$2.0M
SG&A Expenses	N/A	$3.6M-5.3%	$3.8M-11.7%	$4.3M	N/A	$1.8M+87.4%	$976K+62.1%	$602K
Operating Income	N/A	-$12.7M-4.0%	-$12.3M-18.4%	-$10.4M	N/A	-$37.8M-804.0%	-$4.2M-63.4%	-$2.6M
Interest Expense	N/A	$0	$0-100.0%	$1.4M	N/A	$815K+63.3%	$499K+539.7%	$78K
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	$0	$0
Net Income	N/A	-$11.9M-4.8%	-$11.3M-11.3%	-$10.2M	N/A	-$38.1M-574.1%	-$5.7M-65.8%	-$3.4M
EPS (Diluted)	N/A	$-0.64-4.9%	$-0.61	$-2.52	N/A	$-28.16-561.0%	$-4.26-63.8%	$-2.60

KLRS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$121.7M+1875.6%	$6.2M-96.8%	$190.8M-31.1%	$277.1M-3.3%	$286.6M-22.7%	$370.8M
Current Assets	$118.8M+4459.1%	$2.6M-98.6%	$187.6M-22.8%	$243.1M-4.1%	$253.3M-29.9%	$361.3M
Cash & Equivalents	$98.1M+5882.6%	$1.6M-98.2%	$90.1M-15.1%	$106.1M-47.4%	$201.7M+64.4%	$122.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$42.9M-58.2%	$102.8M-56.4%	$235.8M+348.7%	$52.6M-14.3%	$61.3M+245.4%	$17.8M
Current Liabilities	$9.7M-60.7%	$24.7M-12.9%	$28.4M+16.6%	$24.3M-35.7%	$37.9M+207.9%	$12.3M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$78.8M+181.6%	-$96.6M-114.6%	-$45.0M-120.1%	$224.5M-0.3%	$225.3M-36.2%	$353.1M
Retained Earnings	-$160.0M-37.3%	-$116.6M+82.2%	-$656.2M-40.9%	-$465.8M-56.8%	-$297.1M-137.5%	-$125.1M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$121.7M+50.0%	$81.2M-12.6%	$92.8M-9.9%	$103.1M+1573.0%	$6.2M-95.0%	$122.5M-6.5%	$131.0M-9.1%	$144.1M
Current Assets	$118.8M+52.0%	$78.2M-14.7%	$91.7M-10.3%	$102.2M+3821.0%	$2.6M-97.9%	$122.5M-5.7%	$129.9M-8.2%	$141.5M
Cash & Equivalents	$98.1M+131.3%	$42.4M-52.1%	$88.4M-12.4%	$101.0M+6060.2%	$1.6M-14.3%	$1.9M-69.3%	$6.2M+19.4%	$5.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$42.9M+9.2%	$39.3M-1.0%	$39.7M+1.3%	$39.2M-61.8%	$102.8M-51.5%	$211.9M+16.1%	$182.5M-4.8%	$191.7M
Current Liabilities	$9.7M+60.2%	$6.1M-20.7%	$7.7M+7.1%	$7.1M-71.1%	$24.7M+1649.5%	$1.4M-40.1%	$2.4M-69.2%	$7.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$78.8M+88.3%	$41.9M-21.2%	$53.1M-16.8%	$63.9M+166.1%	-$96.6M-8.1%	-$89.4M-73.5%	-$51.5M-8.4%	-$47.5M
Retained Earnings	-$160.0M-6.7%	-$150.0M-8.6%	-$138.1M-9.0%	-$126.8M-8.7%	-$116.6M+83.3%	-$696.7M-0.6%	-$692.6M-0.9%	-$686.5M

KLRS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$38.4M-85.6%	-$20.7M+83.4%	-$124.5M+12.4%	-$142.1M-33.6%	-$106.3M-74.8%	-$60.8M
Capital Expenditures	$200K	N/A	N/A	N/A	$26K-88.9%	$235K
Free Cash Flow	-$38.6M	N/A	N/A	N/A	-$106.3M-74.2%	-$61.0M
Investing Cash Flow	-$19.7M	N/A	$38.0M+147.2%	-$80.5M-143.3%	$186.0M+209.7%	-$169.5M
Financing Cash Flow	$155.0M+709.9%	$19.1M-72.8%	$70.5M-44.5%	$127.0M+54624.6%	$232K-99.9%	$292.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$7.1M+37.7%	-$11.3M+9.6%	-$12.5M-68.5%	-$7.4M+5.2%	-$7.9M-81.4%	-$4.3M-9.0%	-$4.0M+12.2%	-$4.5M
Capital Expenditures	$17K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$7.1M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$15.0M	N/A	N/A	N/A	$5.0M-75.0%	$20.0M-33.3%	$30.0M-25.0%	$40.0M
Financing Cash Flow	$47.7M	$0	$0-100.0%	$107.3M+1315.7%	$7.6M+757600.0%	$1K-100.0%	$5.0M-24.3%	$6.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KLRS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-55.1%	N/A	N/A	-75.1%+1.2pp	-76.3%-56.6pp	-19.8%
Return on Assets	-35.7%	N/A	-99.8%-38.9pp	-60.9%-0.9pp	-60.0%-41.2pp	-18.8%
Current Ratio	12.23+12.1	0.11-6.5	6.61-3.4	9.99+3.3	6.69-22.7	29.39
Debt-to-Equity	0.54+1.6	-1.06+4.2	-5.24-5.5	0.23-0.0	0.27+0.2	0.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-28.4%-7.0pp	-21.4%-5.4pp	-16.0%	N/A	N/A	N/A	N/A
Return on Assets	N/A	-14.6%-2.4pp	-12.2%-2.3pp	-9.9%	N/A	-31.1%-26.8pp	-4.3%-1.9pp	-2.4%
Current Ratio	12.23-0.7	12.89+0.9	11.98-2.3	14.31+14.2	0.11-86.7	86.78+31.7	55.08+36.6	18.48
Debt-to-Equity	0.54-0.4	0.94+0.2	0.75+0.1	0.61+1.7	-1.06+1.3	-2.37+1.2	-3.54+0.5	-4.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Acumen Pharmaceuticals, Inc. ABOS

$185.6M

Immunic Inc IMUX

$12.0M

Nutriband Inc NTRB

$48.6M

Anebulo Pharmaceuticals Inc ANEB

$14.7M

Sutro Biopharma STRO

$552.2M

Frequently Asked Questions

Is Kalaris Therapeutics Inc profitable?

No, Kalaris Therapeutics Inc (KLRS) reported a net income of -$43.4M in fiscal year 2025.

What is Kalaris Therapeutics Inc's EBITDA?

Kalaris Therapeutics Inc (KLRS) had EBITDA of -$46.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kalaris Therapeutics Inc's return on equity (ROE)?

Kalaris Therapeutics Inc (KLRS) has a return on equity of -55.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Kalaris Therapeutics Inc's free cash flow?

Kalaris Therapeutics Inc (KLRS) generated -$38.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kalaris Therapeutics Inc's operating cash flow?

Kalaris Therapeutics Inc (KLRS) generated -$38.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Kalaris Therapeutics Inc's total assets?

Kalaris Therapeutics Inc (KLRS) had $121.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kalaris Therapeutics Inc's capital expenditures?

Kalaris Therapeutics Inc (KLRS) invested $200K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kalaris Therapeutics Inc spend on research and development?

Kalaris Therapeutics Inc (KLRS) invested $30.8M in research and development during fiscal year 2025.

How many shares does Kalaris Therapeutics Inc have outstanding?

Kalaris Therapeutics Inc (KLRS) had 23M shares outstanding as of fiscal year 2025.

What is Kalaris Therapeutics Inc's current ratio?

Kalaris Therapeutics Inc (KLRS) had a current ratio of 12.23 as of fiscal year 2025, which is generally considered healthy.

What is Kalaris Therapeutics Inc's debt-to-equity ratio?

Kalaris Therapeutics Inc (KLRS) had a debt-to-equity ratio of 0.54 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kalaris Therapeutics Inc's return on assets (ROA)?

Kalaris Therapeutics Inc (KLRS) had a return on assets of -35.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Kalaris Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Kalaris Therapeutics Inc (KLRS) had $98.1M in cash against an annual operating cash burn of $38.4M. This gives an estimated cash runway of approximately 31 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Kalaris Therapeutics Inc's Piotroski F-Score?

Kalaris Therapeutics Inc (KLRS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kalaris Therapeutics Inc's earnings high quality?

Kalaris Therapeutics Inc (KLRS) has an earnings quality ratio of 0.88x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kalaris Therapeutics Inc cover its interest payments?

Kalaris Therapeutics Inc (KLRS) has an interest coverage ratio of -32.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Kalaris Therapeutics Inc?

Kalaris Therapeutics Inc (KLRS) scores 32 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.